Delivery Order SPE2DR25D1004-SPE2DR26FSVD5
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $1,148.34 to AmerisourceBergen Drug Corp for Sacubitril-Valsartan 24-26 mg tablets (180-count supply) with a firm fixed price structure. This non-competitive delivery order, issued on November 17, 2025, is scheduled for completion by November 18, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The award represents a continuation of pharmaceutical supply support under...
- The Defense Logistics Agency awarded a delivery order valued at $18,186.68 to AmerisourceBergen Drug Corp for the supply of Sacubitril-Valsartan 24-26 mg tablets (60 count) on September 9, 2025, with a completion date of September 10, 2025. This is a firm fixed-price delivery order with no set-aside designation, awarded through open competition. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate headquarters...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 15, 2025, for the supply of Sacubitril-Valsartan 24-26 mg tablets (60-count) valued at $2,202.57. This is a firm fixed-price, non-set-aside contract with performance to be completed by September 16, 2025, and fulfillment occurring at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. The award represents a delivery order under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $15,166.08 for Sacubitril-Valsartan 97-103 mg tablets (60-count) on September 22, 2025, with completion scheduled for September 23, 2025. This firm fixed price delivery order was competitively awarded with no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The contract represents a routine pharmaceutical procurement supporting federal medical...
- The Defense Logistics Agency awarded a $44,508.93 delivery order to AmerisourceBergen Drug Corp for the supply of Sacubitril-Valsartan 49-51 mg tablets (180-count supply) under a firm fixed price contract structure. The award was issued on September 5, 2025, with an ultimate completion date of September 8, 2025, and represents a non-set-aside, competitively awarded procurement. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform this order at its corporate...
- The Defense Logistics Agency awarded a delivery order valued at $6,183.25 to AmerisourceBergen Drug Corp for Sacubitril-Valsartan 49-51 mg tablets (60-count supply) on November 4, 2025, with completion scheduled for November 5, 2025. This is a firm fixed-price delivery order with no set-aside designation, awarded through open competition to the Conshohocken, Pennsylvania-based pharmaceutical distributor. The award falls under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop...
- The Defense Logistics Agency awarded a delivery order valued at $3,655.03 to AmerisourceBergen Drug Corp for the supply of Sacubitril-Valsartan 24-26 mg tablets (180-count unit) on November 6, 2025, with completion scheduled for November 7, 2025. The contract utilizes firm fixed pricing with no set-aside designation, indicating competitive award status. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving federal medical procurement...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Sacubitril-Valsartan 49-51 mg tablets (180 count) with a ceiling value of $2,236.69. This competitively awarded, firm fixed-price delivery order has an ultimate completion date of November 17, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a non-set-aside procurement, reflecting the contractor's demonstrated...
- The Defense Logistics Agency awarded a delivery order valued at $3,891.74 to AmerisourceBergen Drug Corp for Sacubitril-Valsartan 49-51 mg tablets (60-count) on November 18, 2025, with completion expected by November 19, 2025. This is a firm fixed-price, competitively awarded delivery order with no set-aside designation. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor and critical vendor for federal medical procurement, particularly...
- The Defense Logistics Agency awarded a delivery order valued at $3,856.70 to AmerisourceBergen Drug Corp for the supply of Sacubitril-Valsartan 24-26 mg in quantities of 60 tablets. This competitively awarded, firm fixed-price delivery order is scheduled for completion by November 17, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The contract carries no set-aside designation, indicating that AmerisourceBergen Drug Corp competed against...
- SPE2DR25D1004Indefinite Delivery Contract
- SPE2DR25D1004-SPE2DR26FSVD5Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $1,446.94 to AmerisourceBergen Drug Corp for the supply of Sacubitril-Valsartan 49-51 mg tablets (180-count unit) on November 18, 2025. This competitively awarded, firm fixed-price delivery order is set to be completed by November 19, 2025, with performance taking place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a routine pharmaceutical procurement supporting federal medical supply requirements for military and veteran healthcare systems. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (SPE2DX) with DLA Troop Support Medical, a comprehensive global pharmaceutical support vehicle valued at $999,999,999.00 and extending through December 2026. As the prime contractor under this IDC, AmerisourceBergen supplies a broad range of pharmaceutical products and medical commodities to support Defense Health Agency operations and other federal healthcare systems worldwide. The firm's track record of competitive awards and versatile fulfillment capabilities across multiple therapeutic domains demonstrates its established role as a critical pharmaceutical vendor within the federal medical supply chain.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.4k | 11/18/25 |